Digoxin and cognitive performance in patients with heart failure: A cohort, pharmacoepidemiological survey

Drugs and Aging

Volumn 26, Issue 2, 2009, Pages 103-112

  Laudisio, Alice ^a   Marzetti, Emanuele ^b   Pagano, Francesco ^a   Cocchi, Alberto ^a   Bernabei, Roberto ^a   Zuccalà, Giuseppe ^a  

^a Catholic University School of Medicine   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cognitive function; Digoxin, pharmacodynamics; Elderly

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; COGNITIVE DEFECT; FEMALE; HEART FAILURE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; COGNITION; DIGOXIN; FEMALE; HEART FAILURE; HUMANS; ITALY; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY;

EID: 60249100017     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200926020-00002     Document Type: Article

References (46)

1. McCullough PA, Philbin EF, Spertus JA, et al. Resource Utilization Among Congestive Heart Failure (REACH) Study. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002; 39: 60-9
2. Zuccalà G, Cattel C, Manes-Gravina E, et al. Left ventricular dysfunction: a clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997; 63: 509-12
3. Zuccalà G, Onder G, Pedone C, et al. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology 2001; 59: 1986-92
4. Almeida OP, Flicker L. The mind of a failing heart: a systematic review of the association between congestive heart failure and cognitive functioning. Intern Med J 2001; 31: 290-5
5. Zuccalà G, Onder G, Pedone C, et al. Cognitive dysfunction as a major determinant of disability in patients with heart failure: results from a multicentre survey. J Neurol Neurosurg Psychiatry 2001; 70: 109-12
6. Zuccalà G, Pedone C, Cesari M, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 2003; 115: 97-103
7. Pullicino PM, Hart J. Cognitive impairment in congestive heart failure? Embolism vs hypoperfusion. Neurology 2001; 57: 1945-6
8. Roman GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci 2002; 203-204: 7-10
9. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159: 1690-700
10. Koide H, Kobayashi S, Kitani M, et al. Improvement of cerebral blood flow and cognitive function following pacemaker implantation in patients with bradycardia. Gerontology 1994; 40: 279-85
11. Grimm M, Yeganehfar W, Laufer G, et al. Cyclosporine may affect improvement of cognitive brain function after successful cardiac transplantation. Circulation 1996; 94: 1339-45
12. Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005; 26: 226-33
13. Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 2006; 12: 343-6
14. Vatta M, Pena C, Fernandez BE, et al. Endobain E, a brain Na+, K+ -ATPase inhibitor, decreases norepinephrine uptake in rat hypothalamus. Life Sci 2004; 76: 359-65
15. Reines A, Zarate S, Carmona C, et al. Endobain E, a brain endogenous factor, is present and modulates NMDA receptor in ischemic conditions. Life Sci 2005; 78: 245-52
16. Kilander L, Andren B, Nyman H, et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998; 29: 1816-20
17. Carosella L, Pahor M, Pedone C, et al. Pharmacosurveillance in hospitalized patients in Italy. Study design of the 'Gruppo Italiano di Farmacovigilanza nell'Anziano' (GIFA). Pharmacol Res 1999; 40: 287-95
18. Pahor M, Chrischilles EA, Guralnik JM, et al. Drug data coding and analysis in epidemiologic studies. Eur J Clin Epidemiol 1994; 10: 405-11
19. Antonelli Incalzi R, Pedone C, Pahor M, et al. Reasons prompting digitalis therapy in the acute care hospital. J Gerontol Med Sci 2001; 56: M361-5
20. Carlson KJ, Lee DC, Goroll AH, et al. An analysis of physicians' reasons for prescribing long-term digitalis therapy in out-patients. J Chron Dis 1985; 38: 733-9
21. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972; 1: 233-8
22. Gomez de Caso JA, Rodriguez-Artalejo F, Claveria LE, et al. Value of Hodkinson's test for detecting dementia and mild cognitive impairment in epidemiological surveys. Neuroepidemiology 1994; 13: 64-8
23. Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 1996; 12: 608-11
24. La Rocca WA, Bonaiuto S, Lippi A, et al. Validation of the Hodkinson abbreviated mental test as a screening instrument for dementia in an Italian population. Neuroepidemiology 1992; 11: 288-95
25. PHS-HCFA. International classification of diseases, 9th rev. Washington, DC: Public Health Service-Health Care Financing Administration, 1980
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9
28. Zuccalà G, Marzetti E, Cesari M, et al. Correlates of cognitive impairment among patients with heart failure: results of a multicenter survey. Am J Med 2005; 118: 496-502
29. Lee CW, Lee JH, Lim TH, et al. Prognostic significance of cerebral metabolic abnormalities in patients with congestive heart failure. Circulation 2001; 103: 2784-7
30. Royall DR, Palmer R, Chiodo LK, et al. Executive control mediates memory's association with change in instrumental activities of daily living: the Freedom House Study. J Am Geriatr Soc 2005; 53: 11-7
31. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993; 126: 141-6
32. Melamed E, Lavy S, Bentin S, et al. Reduction in regional cerebral blood flow during normal aging in man. Stroke 1980; 11: 31-5
33. Georgiadis E, Sievert M, Cencetti S, et al. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000; 21: 407-13
34. Raiha I, Tarvonen S, Kurki T, et al. Relationship between vascular factors and white matter low attenuation of the brain. Acta Neurol Scand 1993; 87: 286-9
35. Tarvonen S, Roytta M, Raiha I, et al. Clinical features of leukoaraiosis. J Neurol Neurosurg Psychiatry 1996; 60: 431-6
36. Van den Heuvel DM, Ten Dam VH, de Craen AJ, et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry 2006; 77: 149-53
37. Cummings JL. Vascular subcortical dementias: clinical aspects. Dementia 1994; 5: 177-80
38. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27: 178-86
39. Smith TW. The basic mechanism of inotropic action of digitalis glycosides. J Pharmacol 1984; 15 Suppl. 1: 35-51
40. Zuccala G, Pedone C, Carosella L, et al. Optimum dose of digoxin [letter]. Lancet 1997; 349: 1845
41. Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998; 50: 597-664
42. Baskys A, Blaabjerg M. Understanding regulation of nerve cell death by mGluRs as a method for development of successful neuroprotective strategies. J Neurol Sci 2005; 229-230: 201-9
43. Cheung WJ, Kent MA, El-Shahat E, et al. Central and peripheral renin-angiotensin systems in ouabain-induced hypertension. Am J Physiol Heart Circ Physiol 2006; 29: H624-30
44. Lou M, Blume A, Zhao Y, et al. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurological deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 2004; 24: 536-47
45. Dai WJ, Funk A, Herdegen T, et al. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30: 2391-9
46. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22: 23-45